In The News View All

  • Safety of Sodium-Glucose Co-Transporter 2 Inhibitors
    Sodium-glucose co-transporter 2 (SGLT2) inhibitors have a well-defined safety profile based on data obtained from numerous clinical trials, including cardiovascular outcomes trials (CVOTs) and postmarketing pharmacovigilance reporting. Adverse events including risk of genital mycotic infection and volume depletion-related events are ...
    Published on 2019-11-18

Authors